Takeda Pharmaceutical Co. Ltd.

Model N Appoints Thomas Gibbs to Board of Directors

British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care